Secondary tumours in Sjögren's syndrome

Autoimmunity Reviews

Volumn 9, Issue 4, 2010, Pages 203-206

  Kovács, László ^a   Szodoray, Peter ^b   Kiss, Emese ^c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

^c NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

Author keywords

Activation induced cytidin deaminase; B lymphocyte activating factor; Chemokine; Lymphoma; Marginal zone B cell; Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; CXCL13 CHEMOKINE; IMMUNOGLOBULIN; INTERLEUKIN 10; SECONDARY LYMPHOID TISSUE CHEMOKINE;

B CELL LYMPHOMA; B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL FEATURE; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; EXOCRINE GLAND; HUMAN; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; MARGINAL ZONE LYMPHOMA; NEOPLASM; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; PREVALENCE; PROTEIN URINE LEVEL; PURPURA; REVIEW; SJOEGREN SYNDROME; VASCULITIS;

B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHORISTOMA; HUMANS; LYMPHATIC DISEASES; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; RHEUMATOID FACTOR; SJOGREN'S SYNDROME; VASCULITIS;

EID: 73649089004     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.07.002     Document Type: Review

References (40)

1. Lazarus M.N., Robinson D., Mak V., Moller H., and Isenberg D.A. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology 45 (2006) 1012-1015
2. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89 (1978) 888-892
3. Vinagre F., Santos M.J., Prata A., Canas da Silva J., and Santos A.I. Assessment of salivary gland function in Sjögren's syndrome: the role of salivary gland scintigraphy. Autoimm Rev 8 (2009) 672-676
4. Kauppi M., Pukkala E., and Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8 (1997) 201-204
5. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer, doi: 10.1002/ijc.24287.
6. Voulgarelis M., Dafni U.G., Isenberg D.A., and Moutsopoulos H. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action of Sjögren's syndrome. Arthritis Rheum 42 (1999) 1765-1772
7. Pariente D., Anaya J.M., Combe B., Jorgensen C., Emberger J.M., Rossi J.F., et al. Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med 1 (1992) 337-342
8. Sutcliffe N., Inanc M., Speight P., and Isenberg D. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 28 (1998) 80-87
9. Royer B.D., Cazals-Hatem J., Sibilila F., Agbalika J.M., Cayuela T., Sossi F., et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90 (1997) 766-775
10. Skopouli F.N., Dafni U., Ioannidis J.P.A., and Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 29 (2000) 296-304
11. Tzioufas A.G., Boumba D.S., Skopouli F.N., and Moutsopoulos H.M. Mixed monoclonal cryoglobulinaemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 39 (1996) 767-772
12. Bombardieri M., Barone F., Humby F., Kelly S., McGurk M., Morgan P., et al. Acitvation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome. J Immunol 179 (2007) 4929-4938
13. Bahler D.W., and Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as non-malignant antigen-selected expansions. Blood 91 (1998) 1864-1872
14. Streubel B., Huber D., Wöhrer S., Chott A., and Raderer M. Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjögren's syndrome. Clin Cancer Res 10 (2004) 476-480
15. Tapinos N.I., Polihronis M., and Moutsopoulos H.M. Lymphoma development in Sjögren's syndrome. Novel p53 mutations. Arthritis Rheum 42 (1999) 1466-1472
16. Katsikis P.D., Youinou P.Y., Galanopoulou V., Papadopoulos N.M., Tzioufas A.G., and Moutsopoulos H.M. Monoclonal process in primary Sjögren's syndrome and cross-reactive idiotype associated with rheumatoid factor. Clin Exp Immunol 82 (1990) 509-514
17. Bahler D., Miklos J.A., and Swerdlow S.H. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 89 (1997) 3335-3344
18. Daridon C., Youinou P., and Pers J.O. BAFF, APRIL, TWE-PRIL: Who's who?. Autoimm Rev 7 (2008) 267-273
19. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLys overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109 (2002) 59-66
20. Lavie F., Miceli-Richard C., Quillard J., Roux S., Leclerc P., and Mariette X. Expression of BAFF (BLyS) in T cell infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 202 (2004) 496-502
21. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., and Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 25 (2005) 189-201
22. Szodoray P., Alex P., Jonsson M.V., Knowlton N., Dozmorov I., Nakken B., et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117 (2005) 168-176
23. Novak A.J., Grote D.M., Stenson M., Ziesmer S.C., Witzig T.E., Habermann T.M., et al. Expression of BLyS and its receptors in B-cell non-Hodgkin's lymphoma: correlation with disease activity and patient outcome. Blood 104 (2004) 2247-2253
24. Ohlsson M., Szodoray P., Loro L.L., Johannessen A.C., and Jonsson R. CD40, CD154, Bax and Bcl-2 expression in Sjögren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand J Immunol 56 (2002) 561-571
25. De Vita S., Quartuccio L., and Fabris L. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimm Rev 8 (2008) 95-99
26. Ceribelli A., Cavazzana I., Cattaneo R., and Franceschini F. Hepatitis C virus infection and primary Sjögren's syndrome. A clinical and serologic description of 9 patients. Autoimm Rev 8 (2008) 92-94
27. Marcos M., Alvarez F., Brito-Zerón P., Bove A., Perez-De-Lis M., Diaz-Lagares C., et al. Chronic hepatitis B virus infection in Sjögren's syndrome. Prevalence and clinical significance in 603 patients. Autoimm Rev 8 (2009) 616-620
28. Doria A., Zampieri S., and Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimm Rev 8 (2008) 89-91
29. Yamada T., Zhang K., Yamada A., Zhu D., and Saxon A. B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am J Respir Cell Mol Biol 32 (2005) 388-394
30. Guzman Moreno R. B cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimm Rev 8 (2009) 585-590
31. Quartuccio L., Fabris M., Moretti M., Barone F., Bombardieri M., Rupolo M., et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheum J 2 (2008) 38-423
32. Cornec D., Avouac J., Youinou P., and Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimm Rev 9 (2009) 515-519
33. Barten M., Fletcher C., Ng L.G., Groom J., Wheway J., Laabi Y., et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 172 (2004) 812-822
34. Xu L.G., and Shu H.B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol 169 (2004) 6883-6889
35. Villarreal G.M., Alcocer-Varela J., and Llorente L. Differential interleukin (IL)-10 and IL-13 gene expression in vivo in salivary glands and peripheral blood mononuclear cells from patients with primary Sjögren's syndrome. Immunol Lett 49 (1996) 105-109
36. De Vita S., Dolcetti R., Ferraccioli G., Pivetta B., De Re V., Gloghini A., et al. Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. J Rheumatol 22 (1995) 1674-1680
37. Mitsias D.I., Tzioufas A.G., Veiopoulou C., Zintzaras E., Tassios I.K., Kogopoulou O., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 128 (2002) 562-568
38. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 46 (2002) 2160-2171
39. Jacobi A.M., Odendahl M., et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 1332-1342
40. Barone F., Bombardieri M., Rosado M.M., Morgan P.R., Challacombe S.J., De Vita S., et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 180 (2008) 5130-5140